FATE Q4 2020 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+467.3% YoY

Gross Profit

-$23M-145.2% margin

Operating Income

-$33M-210.1% margin

Net Income

-$53M-334.1% margin

EPS (Diluted)

$-0.61

QoQ Revenue Growth

+110.3%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$23M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$622M

Total Liabilities

$238M

Stockholders' Equity

$384M

Cash & Equivalents

$167M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$3M	+467.3%
Gross Profit	-$23M	$3M	-923.9%
Operating Income	-$33M	-$29M	-14.9%
Net Income	-$53M	-$28M	-87.7%